Abbott Laboratories

Summary

Organization: Abbott Laboratories
Country: USA

Top Publications

  1. doi In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107
    John Malysz
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064 6125, USA
    J Pharmacol Exp Ther 334:863-74. 2010
  2. ncbi Confounding effects of volatile anesthesia on CBV assessment in rodent forebrain following ethanol challenge
    Feng Luo
    Experimental Imaging Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Magn Reson Imaging 26:557-63. 2007
  3. ncbi Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy
    S Dutta
    Clinical Pharmacokinetics, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Clin Pharm Ther 32:365-71. 2007
  4. ncbi AMPA receptor antagonists reverse effects of extended habit training on signaled food approach responding in rats
    A Y Bespalov
    Neuroscience Research, GPRD, Abbott, 67008, Ludwigshafen, Germany
    Psychopharmacology (Berl) 195:11-8. 2007
  5. ncbi Characterization of lower molecular weight artifact bands of recombinant monoclonal IgG1 antibodies on non-reducing SDS-PAGE
    Hongcheng Liu
    Protein Analytics, Process Sciences Department, Abbott Bioresearch Center, Worcester, MA, 01605, USA
    Biotechnol Lett 29:1611-22. 2007
  6. ncbi In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists
    Richard J Perner
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 50:3651-60. 2007
  7. ncbi Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS
    Raymond Naxing Xu
    Abbott Laboratories, Department of Drug Analysis, 100 Abbott Park Road, Abbott Park, IL 60064 6126, USA
    J Pharm Biomed Anal 44:342-55. 2007
  8. ncbi Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment
    Peter Curzon
    Neuroscience Research, Abbott Laboratories GPRD, Abbott Park, IL 60064 6115, United States
    Neurosci Lett 410:15-9. 2006
  9. ncbi Effect of a viscous fiber bar on postprandial glycemia in subjects with type 2 diabetes
    Ann M Flammang
    Ross Products Division of Abbott, 3300 Stelzer Rd, Columbus, OH 43219 3034, USA
    J Am Coll Nutr 25:409-14. 2006
  10. ncbi Validation and application of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma using semi-automated 96-well liquid-liquid extraction
    Perry G Wang
    Drug Analysis Department, Abbott Laboratories, Abbott Park, IL 60064, USA
    J Chromatogr A 1130:302-7. 2006

Detail Information

Publications62

  1. doi In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107
    John Malysz
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064 6125, USA
    J Pharmacol Exp Ther 334:863-74. 2010
    ..In summary, ABT-107 is a selective high affinity alpha7 nAChR agonist suitable for characterizing the roles of this subtype in pharmacological studies...
  2. ncbi Confounding effects of volatile anesthesia on CBV assessment in rodent forebrain following ethanol challenge
    Feng Luo
    Experimental Imaging Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Magn Reson Imaging 26:557-63. 2007
    ..To compare and contrast the pattern and characteristics of the cerebral blood volume (CBV) response to ethanol (EtOH) in rats under awake and anesthetized conditions...
  3. ncbi Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy
    S Dutta
    Clinical Pharmacokinetics, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Clin Pharm Ther 32:365-71. 2007
    ..To characterize protein binding in patients with epilepsy who achieve transient high (>150 mg/L) total plasma concentrations following rapid valproate infusion at very high doses...
  4. ncbi AMPA receptor antagonists reverse effects of extended habit training on signaled food approach responding in rats
    A Y Bespalov
    Neuroscience Research, GPRD, Abbott, 67008, Ludwigshafen, Germany
    Psychopharmacology (Berl) 195:11-8. 2007
    ....
  5. ncbi Characterization of lower molecular weight artifact bands of recombinant monoclonal IgG1 antibodies on non-reducing SDS-PAGE
    Hongcheng Liu
    Protein Analytics, Process Sciences Department, Abbott Bioresearch Center, Worcester, MA, 01605, USA
    Biotechnol Lett 29:1611-22. 2007
    ..Breakage of disulfide bonds by beta-elimination was evidenced by the detection of dehydroalanine using mass spectrometry...
  6. ncbi In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists
    Richard J Perner
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 50:3651-60. 2007
    ..Further optimization of 45 resulted in compound 58 with substantially improved microsome stability and oral bioavailability, as well as in vivo activity...
  7. ncbi Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS
    Raymond Naxing Xu
    Abbott Laboratories, Department of Drug Analysis, 100 Abbott Park Road, Abbott Park, IL 60064 6126, USA
    J Pharm Biomed Anal 44:342-55. 2007
    ..In the end, this paper also discusses recent studies of matrix effect in LC-MS/MS analysis and how to reduce/eliminate matrix effect in method development and validation...
  8. ncbi Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment
    Peter Curzon
    Neuroscience Research, Abbott Laboratories GPRD, Abbott Park, IL 60064 6115, United States
    Neurosci Lett 410:15-9. 2006
    ....
  9. ncbi Effect of a viscous fiber bar on postprandial glycemia in subjects with type 2 diabetes
    Ann M Flammang
    Ross Products Division of Abbott, 3300 Stelzer Rd, Columbus, OH 43219 3034, USA
    J Am Coll Nutr 25:409-14. 2006
    ..To compare the effect of an experimental viscous fiber (VF) crispy bar on the postprandial glucose, insulin, and C-peptide response in adult subjects with type 2 diabetes to two commercially available control crispy bars...
  10. ncbi Validation and application of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of lopinavir and ritonavir in human plasma using semi-automated 96-well liquid-liquid extraction
    Perry G Wang
    Drug Analysis Department, Abbott Laboratories, Abbott Park, IL 60064, USA
    J Chromatogr A 1130:302-7. 2006
    Kaletra is an important antiretroviral drug, which has been developed by Abbott Laboratories. It is composed of lopinavir (low-pin-a-veer) and ritonavir (ri-toe-na-veer)...
  11. ncbi Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121
    Jia Bao Pan
    Neuroscience Research, Abbott Laboratories, 100 Abbott Road, Abbott Park, IL 60064 6125, USA
    Life Sci 79:1366-79. 2006
    ..The implications for potential long-term treatment with H(3) receptor antagonists in CNS disorders such as ADHD are discussed...
  12. ncbi Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety
    Gary A Gintant
    Deptartment of Integrative Pharmacology, Abbott Laboratories, Abbott Park, Illinois 60064 6119, USA
    Toxicol Pathol 34:81-90. 2006
    ..e., overt and covert hERG blockade due to multichannel block) together with the utility and limitations of hERG assays as tools to predict the risk of delayed repolarization and proarrhythmia are discussed...
  13. ncbi Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors
    John T Randolph
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem 14:4035-46. 2006
    ..The 3-pyridylmethyl analog 30 gave the best overall exposure (rat AUC=7.1 microg h/mL and dog AUC=4.9 microg h/mL), however, this compound was found to be a potent inhibitor of cytochrome P450 3A (Ki=2.4 nM)...
  14. ncbi Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors
    Gaoquan Li
    Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 16:2293-8. 2006
    ..7 microM) and enhanced doxorubicin cytotoxicity (IC50=0.44 microM) while displaying no single agent activity...
  15. ncbi Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors
    Zhi Fu Tao
    Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 17:5944-51. 2007
    ..The current work paved the way to the identification of several potent Chk1 inhibitors with good pharmacokinetics that are suitable for in vivo study with oral dosing...
  16. ncbi Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists
    Robert J Altenbach
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064 6123, USA
    J Med Chem 50:5439-48. 2007
    ..Further studies on the pharmaceutic properties of this series of quinolines discovered a potential problem with photochemical instability, an issue which contributed to the discontinuation of this series from further development...
  17. ncbi Analgesic activity of metabotropic glutamate receptor 1 antagonists on spontaneous post-operative pain in rats
    Chang Z Zhu
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 3500, USA
    Eur J Pharmacol 580:314-21. 2008
    ....
  18. doi Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition
    Gerard J Marek
    Abbott Laboratories, GPRD, R48B, AP04 01, 100 Abbott Park Road, Abbott Park, IL 60064 6075, USA
    Eur J Pharmacol 639:81-90. 2010
    ....
  19. doi Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems
    L E Leigh Perkins
    Abbott Vascular, 359 Dudley Ferry Road, Mattaponi, VA 23110, USA
    Vet Pathol 47:58-76. 2010
    ..In this review, preclinical models of restenosis are presented, and their application and limitation in the evaluation of device-based interventional technologies for the treatment of CAD are discussed...
  20. doi Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease
    Nathan R Rustay
    Neuroscience Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Rd, Bldg AP4 2, Abbott Park, IL 60064, USA
    Brain Res 1311:136-47. 2010
    ..These results indicate that mice on the 129 genetic background may generate more consistent and robust behavioral differences, providing a useful model for testing therapeutic agents for Alzheimer's disease...
  21. pmc Unusual water-mediated antigenic recognition of the proinflammatory cytokine interleukin-18
    Maria A Argiriadi
    Department of Biochemistry, Abbott Laboratories, Worcester, Massachusetts 01605, USA
    J Biol Chem 284:24478-89. 2009
    ..Thus, counterintuitively, tight and specific antibody binding may in some cases be water-mediated...
  22. ncbi Neuropathic pain: models and mechanisms
    Michael F Jarvis
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6123, USA
    Curr Pharm Des 15:1711-6. 2009
    ....
  23. doi Electrophysiologic characterization of a novel hERG channel activator
    Zhi Su
    Department of Integrative Pharmacology, Abbott Laboratories, R46R AP9, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Biochem Pharmacol 77:1383-90. 2009
    ..In conclusion, A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization...
  24. doi Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well
    Rubina Mondal
    Antiviral Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Antiviral Res 82:82-8. 2009
    ....
  25. doi Purification of high-throughput organic synthesis libraries by counter-current chromatography
    Frank L Wagenaar
    Abbott Laboratories, Abbott Park, IL 60064, USA
    J Chromatogr A 1216:4154-60. 2009
    ..It was also found that dimethyl sulfoxide (DMSO) and DMSO-methanol were suitable as sample injection solvents when using the HEMW solvent systems...
  26. doi Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling
    Yunsong Tong
    Cancer Research, Global Pharmaceutical R and D, Abbott Laboratories, R47S, AP10, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 18:5206-8. 2008
    ..5 and 43.5 nM against Pim-1 and Pim-2, respectively. Compound 19 also exhibited an activity profile with a high degree of kinase selectivity...
  27. doi ATP-gated P2X cation-channels
    Michael F Jarvis
    Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Neuropharmacology 56:208-15. 2009
    ..In this article we have tried to present as much information as possible in two tables in the hope this will be useful as a day-to-day resource, and also because an excellent and detailed review has recently been published...
  28. pmc Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy
    Rukmini Rajagopalan
    Abbott Laboratories, Abbott Park, IL, USA
    AIDS Care 20:1197-201. 2008
    ..28-0.43). HIV-infected patients already experience a considerable deficiency in HRQL compared to general population; this study demonstrates that lipoatrophy further enhances that negative impact on HRQL...
  29. doi Isocyanide-based multicomponent reactions in drug discovery
    Irini Akritopoulou-Zanze
    R4CP, AP10 101, Abbott Laboratories, Abbott Park, IL 60064 6099, USA
    Curr Opin Chem Biol 12:324-31. 2008
    ..Additionally, they were active against a variety of targets such as enzymes, GPCRs and ion channels. The rational for the chemical biologist to apply such diversity generating chemistries is also discussed...
  30. doi Analysis of gene expression profiles in rat hippocampus following treatment with nicotine and an alpha7 nAChR selective agonist
    Jeffrey F Waring
    Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Neurosci Res 60:266-74. 2008
    ..Overall, our results identify gene expression changes that may contribute to further defining the roles of nAChR activation in cognitive function...
  31. ncbi Block of hERG channel by ziprasidone: biophysical properties and molecular determinants
    Zhi Su
    Department of Integrative Pharmacology, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Biochem Pharmacol 71:278-86. 2006
    ..4 and 1mM at 0mV for Y652A and F656A, respectively). In conclusion, ziprasidone preferentially binds to and blocks open hERG channels. Tyr-652 and Phe-656 are two critical residues in the ziprasidone-binding site...
  32. ncbi Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists
    Philip R Kym
    Metabolic Disease Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 48:5888-91. 2005
    ..These results highlight the need for scrutiny of the cardiovascular safety profile of MCHr1 antagonists...
  33. ncbi Measuring antibody affinity and performing immunoassay at the single molecule level
    Sergey Y Tetin
    Drug Monitoring, Abbott Diagnostics Division, Abbott Park, IL 60064 6016, USA
    Anal Biochem 307:84-91. 2002
    ..Fitting of the FCS data for the molar fractions of free and bound fluorescein-labeled vancomycin yielded a calibration curve which could serve for determination of the vancomycin concentration in biological samples...
  34. ncbi Multiple dose pharmacokinetics of fiduxosin under fasting conditions in healthy elderly male subjects
    Sandeep Dutta
    Clinical Pharmacokinetics, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Pharm Pharmacol 54:641-7. 2002
    ..It was concluded that fiduxosin multiple-dose pharmacokinetics were dose-independent and time-invariant over the 30-120 mg/day dose range under fasting conditions...
  35. ncbi Vacuum-assisted lancing of the forearm: an effective and less painful approach to blood glucose monitoring
    D D Cunningham
    Diagnostics Division, Abbott Laboratories, Abbott Park, Illinois 60064 6015, USA
    Diabetes Technol Ther 2:541-8. 2000
    ..Incorporation of a glucose measuring system into the device might improve testing compliance among those who fear pain or the sight of blood...
  36. pmc Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
    D J Kempf
    Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Virol 75:7462-9. 2001
    ....
  37. ncbi Linker-mediated modulation of the chemiluminescent signal from N(10)-(3-Sulfopropyl)-N-sulfonylacridinium-9-carboxamide tracers
    M Adamczyk
    Abbott Laboratories, Diagnostics Division, Department of Chemistry D9NM, Building AP 20, 100 Abbott Park Road, Abbott Park, Illinois 60064 6016, USA
    Bioconjug Chem 11:714-24. 2000
    ....
  38. ncbi Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat
    R S Bitner
    Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Building AP9A LL D 4N5 60064 3500, Abbott Park, IL, USA
    Brain Res 871:66-74. 2000
    ..However, these data do not eliminate the possibility that other nicotinic subunit combinations may also play a role in antinociception produced by nAChR activation...
  39. ncbi Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1
    J R Wu-Wong
    Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois, USA
    J Pharmacol Exp Ther 293:514-21. 2000
    ..These results suggest that the ERK1/2 pathway is activated by ET-1, and blocking this pathway abolishes the antiapoptotic effect of ET-1...
  40. ncbi Cocaine and alcohol interactions in the rat: effect of cocaine and alcohol pretreatments on cocaine pharmacokinetics and pharmacodynamics
    W J Pan
    Pharmacology Toxicology Graduate Program, Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Pullman, Washington 99164 6510, USA
    J Pharm Sci 88:1266-74. 1999
    ..If similar effects occur in humans, chronic cocaine and alcohol abusers may respond differently to cocaine administration compared to naïve users and may be at higher risks of cocaine central nervous system toxicity...
  41. ncbi Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics
    M W Decker
    Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064 6125, USA
    Biochem Pharmacol 58:917-23. 1999
    ....
  42. ncbi Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies
    S L Wong
    Department of Pharmacokinetics and Biopharmaceutics, Abbott Laboratories, Abbott Park, Illinois 60064 3500, USA
    J Pharm Sci 87:1629-31. 1998
    ....
  43. ncbi Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents
    A Hsu
    Abbott Laboratories, Abbott Park, Illinois, USA
    Clin Pharmacokinet 35:275-91. 1998
    ..Other important factors with combination regimens include reduced interpatient variability for high clearance agents, and elimination of the food effect on the bioavailibility of indinavir...
  44. ncbi The loading domain of the erythromycin polyketide synthase is not essential for erythromycin biosynthesis in Saccharopolyspora erythraea
    A Pereda
    Abbott Laboratories, Abbott Park, IL 60064, USA
    Microbiology 144:543-53. 1998
    ..It is proposed that in these mutants the first step in erythromycin biosynthesis is the charging of KS1 with propionate directly from propionyl-CoA...
  45. ncbi Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors
    M W Holladay
    Neurological and Urological Diseases Research D 47W, Abbott Laboratory, Abbott Park, Illinois 60064 3500, USA
    J Med Chem 41:407-12. 1998
    ..Structure-activity studies of analogues related to 4 and 5 suggest that the N-unsubstituted azetidine moiety and the 2-chloro substituent on the pyridine ring are important contributors to potent analgesic activity...
  46. ncbi Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer
    Qun Li
    Abbott Laboratories, Cancer Research, Global Pharmaceutical Discovery, R47S, AP10, 100 Abbott Park Rd, Abbott Park, IL 60064 6101, USA
    Curr Top Med Chem 2:939-71. 2002
    ..A limited number of small molecule inhibitors in this emerging field and their mode of action will be reviewed...
  47. ncbi Evaluating qualitative assays using sensitivity and specificity
    Bob Zhong
    Abbott Laboratories, Abbott Park, IL 60064, USA
    J Biopharm Stat 12:409-24. 2002
    ..Currently, the target-spiking ranges and sample sizes are determined subjectively. This paper presents new acceptance criteria on acceptable conditions and objective standards for selecting the target-spiking range and sample size...
  48. ncbi 1H-Imidazo[4,5-c]quinoline derivatives as novel potent TNF-alpha suppressors: synthesis and structure-activity relationship of 1-, 2-and 4-substituted 1H-imidazo[4,5-c]quinolines or 1H-imidazo[4,5-c]pyridines
    Tomoyuki Izumi
    Research Division, R and D Headquarters, Hokuriku Seiyaku Co, Ltd, 37 1 1, Inokuchi, Katsuyama, Fukui 911 8555, Japan
    Bioorg Med Chem 11:2541-50. 2003
    ..The relation between conformational direction of 2-(4-piperidyl)ethyl group at position 1 and TNF-alpha suppressing activity is also demonstrated by NMR...
  49. ncbi Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity
    Qun Li
    Cancer Research, GPRD, Abbott Laboratories, Abbott Park, IL 60064 6101, USA
    Bioorg Med Chem Lett 15:2918-22. 2005
    ..The current series demonstrate good cellular activity as measured in their inhibiting the Ras processing in NIH-3T3 cells, with compounds 2c and 2f displaying EC(50) values of 18 and 22nM, respectively...
  50. ncbi New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response
    Yan Luo
    Department R47S, Cancer Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Expert Rev Anticancer Ther 5:333-42. 2005
    ..In this review, strategies for implementing small-molecule inhibitors of poly(ADP-ribose) polymerase and Chk1, which are emerging as potential adjuncts to current therapies, are discussed...
  51. ncbi Issues in immunoassay standardization: the ARCHITECT Folate model for intermethod harmonization
    David H Wilson
    Abbott Diagnostics Division, Abbott Laboratories, Abbott Park, IL 60064, USA
    Clin Chem 51:684-7. 2005
  52. ncbi Chkl binds and phosphorylates BAD protein
    Edward Kyu Ho Han
    Department R47S, AP9A, Cancer Research, Global Pharmaceutical Research Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Anticancer Res 24:3907-10. 2004
    ..Taken together, our results suggest that Chk1 may inactivate BAD by associating with and phosphorylating residues critical for BAD function in response to DNA damage...
  53. ncbi Automated 96-well liquid-liquid back extraction liquid chromatography-tandem mass spectrometry method for the determination of ABT-202 in human plasma
    Naxing Xu
    Abbott Laboratories, Department of Clinical Drug Analysis, Dept R46W, Bldg AP13A 2, 100 Abbott Park Road, Abbott Park, IL 60064 6126, USA
    J Pharm Biomed Anal 36:189-95. 2004
    ..994 to 0.997. The method was accurate and reproducible and was successfully applied to generate plasma concentration-time profiles for human subjects after low oral doses of the compound...
  54. ncbi [Dexmedetomidine hydrochloride (Precedex), a new sedative in intensive care, its pharmacological characteristics and clinical study result]
    Kazuko Taiji
    Development and Regulatory, Therapeutic Group 1, Abbott Japan Co, Ltd
    Nihon Yakurigaku Zasshi 124:171-9. 2004
    ..The effective rate for the drug group was significantly high (87.3%; placebo group, 75.0%). The main adverse events observed in the drug group were hypertension and hypotension...
  55. ncbi Technology evaluation: ISIS-113715, Isis
    Gang Liu
    Abbott Laboratories, R4MC, AP10, 100 Abbott Park Road, Abbott Park, IL 6006 6098, USA
    Curr Opin Mol Ther 6:331-6. 2004
    ..Isis is developing ISIS-113715, an antisense inhibitor of the PTP1B gene, for the potential treatment of type 2 diabetes and obesity. ISIS-113715 is undergoing phase II clinical trials...
  56. ncbi Vitamin D analogs as therapeutic agents: a clinical study update
    J Ruth Wu-Wong
    Abbott Laboratories, R4CM Building AP52, 200 Abbott Park Rd, Abbott Park, IL 60064, USA
    Curr Opin Investig Drugs 5:320-6. 2004
    ..This review discusses recent progress on the use of vitamin D and its analogs in the management of HPT secondary to chronic renal disease...
  57. ncbi A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans
    Marlon Cowart
    Department of Neuroscience Research, Abbott Laboratories, Abbott Park, IL 60064 6123, USA
    Bioorg Med Chem Lett 14:689-93. 2004
    ..The SAR of the basic amine moiety was compared in three different series of analogues. The greatest potency was found in analogues bearing a 2-methylpyrrolidine, a 2,5-dimethylpyrrolidine, or a 2,6-dimethylpiperidine...
  58. ncbi Transition metal half-sandwich complexes as redox mediators to glucose oxidase
    Nigel J Forrow
    MediSense UK Ltd, Abbott Laboratories, 14 15 Eyston Way, Abingdon Oxon OX14 1TR, UK
    Biosens Bioelectron 19:763-70. 2004
    ....
  59. ncbi Automated red blood cell differential analysis on a multi-angle light scatter/fluorescence hematology analyzer
    Young Ran Kim
    Department of Core R and D Biotechnology, Abbott Diagnostics Division, Santa Clara, California 95054, USA
    Cytometry B Clin Cytom 56:43-54. 2003
    ..Because of incomplete morphological information on RBC abnormalities, 5-10% of samples in hematology laboratories routinely undergo smear review. A more complete automated RBC differential capability is desired...
  60. ncbi Identification and characterization of novel antagonists of the CCR3 receptor
    Usha Warrior
    Abbott Laboratories, Global Pharmaceutical Products Division, Abbott Park, IL, USA
    J Biomol Screen 8:324-31. 2003
    ..These compounds showed inhibitory effects on eosinophil chemotaxis in both in vitro and in vivo assays...
  61. ncbi Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain
    Lynne E Rueter
    Neurological Research, D4N5 AP9A, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6115, USA
    Pain 103:269-76. 2003
    ..Together these data further support the idea that different mechanisms underlie different pain states and suggest that the effects of NNR agonists in neuropathic pain may be due in part to peripheral actions of the compounds...
  62. ncbi Preparation of succinimidyl and pentafluorophenyl active esters of 5- and 6-carboxyfluorescein
    M Adamczyk
    Diagnostic Division, Abbott Laboratories, Abbott Park, IL 60064 3500, USA
    Bioconjug Chem 8:253-5. 1997
    ..The regioisomeric mixtures were separated to give the 5- and 6-succinimidyl and pentafluorophenyl active esters in > 98% purity...